Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 08/30 04:59:53 pm
316 DKK   +0.89%
08/29 NOVO NORDISK A/ : - Share repurchase programme
08/22 NOVO NORDISK A/ : Helicopter View of A Sustainable City
08/22 NOVO NORDISK A/ : - Share repurchase programme
News SummaryMost relevantAll newsSector news 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
08/29 NOVO NORDISK A/S : - Share repurchase programme
08/25 NOVO NORDISK A/S : Patent Issued for Combination Therapy to Enhance NK Cell Medi..
08/25 NOVO NORDISK A/S : Goulston & Storrs Advises Hana Asset Management-Led Consortiu..
08/25 NOVO NORDISK A/S : HFF Closes $305 Million Sale of Novo Nordisk's Headquarters i..
08/22 NOVO NORDISK A/S : Helicopter View of A Sustainable City
08/22 NOVO NORDISK A/S : - Share repurchase programme
08/15 NOVO NORDISK A/S : - Share repurchase programme
08/15 NOVO NORDISK A/S : HQ sold for $305M to Korean investment company
08/12 NOVO NORDISK A/S : ex-dividend day for interim dividend
08/11 NOVO NORDISK A/S : Report Summarizes Type 2 Diabetes Study Findings from Novo No..
More news
Sector news : Pharmaceuticals - NEC
12:33a ASTRAZENECA : to pay $5.52 million to resolve U.S. SEC foreign bribery case
08/30 U.S. slams EU, but Apple tax demand first issued in Washington
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJFertilizer Producers Agrium and Potash in Merger Talks
08/30DJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/30 Revamping My Dividend Growth Portfolio
08/29 My Updated Portfolio, With 2 Purchases
08/22 Novo Nordisk Vs. Oramed - A Second Look At The Battle For Oral Insulin
08/19 Play Oncology To Play M&A In Big Pharma?
08/18 The Battle For Oral Insulin
Financials ( DKK)
Sales 2016 113 807 M
EBIT 2016 49 524 M
Net income 2016 38 583 M
Finance 2016 14 222 M
Yield 2016 2,29%
P/E ratio 2016 20,55
P/E ratio 2017 18,67
EV / Sales 2016 5,41x
EV / Sales 2017 5,06x
Capitalization 630 335 M
More Financials
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 31
Average target price 378  DKK
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-22.28%94 579
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results